Clinical Trial Update: Immuno-bridging Study of Inactivated SARS-CoV-2 Vaccine in Healthy Population Aged 3-17 vs Aged 18 Years Old and Above [Phase 3]

View source ↗

Summary

Phase 3 immunobridging trial of an inactivated SARS-CoV-2 vaccine in healthy individuals aged 3–17 compared with 18 and older has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Pneumonia

Drugs mentioned

• inactivated SARS-CoV-2 vaccine

Snippet

Sponsor: China National Biotec Group Company Limited | Conditions: COVID-19 Pneumonia, COVID-19 | Phase 3 | Status: COMPLETED